Please login to the form below

SGLT-2

This page shows the latest SGLT-2 news and features for those working in and with pharma, biotech and healthcare.

NICE recommends MSD’s diabetes drug Steglatro

drug. Steglatro is one of the competitors in the sodium-glucose cotransporter-2 (SGLT-2) inhibitor drugs, which are now becoming standard therapy in managing type 2 diabetes (T2D) patients in ... In the UK, the treatment is priced at £29.40 for 28 days,

Latest news

The year of the blockbuster

The diseases targeted by the report’s projected market entrants include type 2 diabetes, endometriosis, childhood epilepsy, haemophilia, HIV, migraine, opioid addiction and shingles. ... Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose
Novo’s diabetes pill defeats Merck’s Januvia in trial

PIONEER 4 saw the enrolment of 711 people with type 2 diabetes inadequately controlled on metformin, or without an SGLT-2 inhibitor. ... Patients achieved a 4.7 and 5.0kg loss compared to 3.2 and 3.1kg with Victoza and 0.7 and 1.2kg with placebo.
FDA panel backs CV claims for Novo Nordisk's Victoza

The positive vote from EMDAC puts us one step closer to expanding our offering to reduce the risk of cardiovascular events in people with type 2 diabetes.". ... Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in
AZ gets US approval for diabetes combo Qtern

The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015. ... The approval of Qtern is good news for patients who may benefit from improved glycaemic control by adding a DPP-4 inhibitor to a
New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients. . ... It is the first time that any diabetes treatment has been approved with a cardiovascular claim and - according to Evercore analyst John Scotti – this could boost

More from news
Approximately 7 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Leading AstraZeneca’s return to growth in Europe

This is the first large real-world evidence study of its kind, evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type 2 diabetes ... receiving treatment with SGLT-2 inhibitors, including AstraZeneca’s
Deal Watch November 2015

2, 700. Cardioxyl Pharmaceuticals. Bristol-Myers Squibb. Acquisition - company. Lead asset: p2 CXL-1427, nitroxyl (HNO) donor (prodrug) - iv treatment for acute decompensated heart failure (ADHF). ... 2, 075. Lexicon Pharmaceuticals. Sanofi.